

**VELOXIS PHARMACEUTICALS A/S  
MINUTES OF GENERAL MEETING**

## **VELOXIS PHARMACEUTICALS A/S**

### **MINUTES OF GENERAL MEETING**

ANNUAL GENERAL MEETING

3 APRIL 2019

(CVR NO.: 26 52 77 67)

On 3 April 2019 at 9 am. CET the annual general meeting of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), was held at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark, with the following agenda:

- 1 Report by the Company's board of directors on the Company's activities during the past financial year
- 2 Presentation of the audited annual report for approval
- 3 Resolution on covering of losses as per the approved annual report
- 4 Election of members to the board of directors
- 5 Election of auditor
- 6 Approval of fee to the board of directors for the financial year 2019
- 7 Proposal by the board of directors on authorization to the board of directors to issue warrants and amendment of the articles of association in accordance therewith
- 8 Proposal by the board of directors for approval of updated remuneration policy including general guidelines for incentive-based remuneration to members of the board of directors and executive management and amendment of the articles of association in accordance therewith
- 9 Proposal from the board of directors to authorize the board of directors to increase the share capital at market price by cash payment with up to nominally DKK 17,181,953.50 with or without pre-emptive subscription rights for the shareholders, including the proposal for amendment of the Company's articles of association in accordance therewith
- 10 Proposal by the board of directors on authorization to the Company to acquire own shares
- 11 Proposal by the board of directors on authorization to the chairman of the annual general meeting, with a right of substitution, to file the resolutions passed at the general meeting for registration with the Danish Business Authority

- 0 -

The chairman of the board of directors, Michael Thomas Heffernan, opened the annual general meeting by welcoming the shareholders and presenting the board of directors and executive management.

Michael Thomas Heffernan informed the general meeting that the board of directors had appointed Attorney-at-Law Thomas Holst Laursen chairman of the meeting in accordance with article 12 of the articles of association.

Thomas Laursen thanked for the election and announced that 82.65% of the voting share capital was represented at the annual general meeting and that the notice to convene the annual general meeting and the publication of the notice complied with the articles of association and Danish statutory provisions. None of the shareholders objected to the legality of the annual general meeting and the chairman of the general meeting announced that the annual general meeting had been duly convened and was legal and

competent in respect of all the items on the agenda.

The chairman of the meeting stated that the general meeting would be held in English without simultaneous translation in accordance with article 8 of the articles of association.

No shareholder requested a complete account of the voting, see section 101(5) and (6) of the Danish Companies Act.

The presentation made at the general meeting is available on the Company's website [www.veloxis.com](http://www.veloxis.com).

- 0 -

The chairman of the meeting proposed that the first three items on the agenda were dealt with together, and as the general meeting did not have any objections, the chairman of the meeting gave the floor to the Company's management.

### **Re 1, 2 and 3**

At the meeting, the management reported on the Company's activities during the past year.

Subsequently, the board of directors proposed that the presented audited annual report was approved.

Further, the board of directors proposed that the previous year's net loss of USD 5.285 million was carried forward by transfer to accumulated deficit.

The board of directors and the management answered questions from the general meeting, including questions relating to distribution of products to patients in the US, opportunities further to FDA approval, the Company's products, US insurance companies' view on the Company's products and the future prospects of the Company.

The chairman of the meeting announced that the general meeting acknowledged the report on the Company's activities during the past year and that the general meeting adopted the annual report for 2018 and passed the resolution on the cover of loss.

### **Re 4**

All existing board members were up for election.

The board of directors proposed re-election of all members of the board of directors, i.e. Michael Thomas Heffernan, Mette Kirstine Agger, Anders Götzsche, Robert Samuel Radie, Lars Kåre Viksmoen and Paul Kevin Wotton.

A description of the qualifications of the nominated candidates was enclosed as appendix 1 to the notice to convene the general meeting.

The proposal was adopted.

### **Re 5**

The board of directors proposed re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the Company's auditor in accordance with the Audit and Risk Management Committee's recommendation.

The proposal was adopted.

### **Re 6**

The board of directors proposed that the general meeting approved the fee to the board of directors for the financial year 2019. The board of directors proposed that the board of directors receives the following

remuneration:

<b>Remuneration to the board of directors and board sub-committees (USD)</b>	<b>2019</b>
Chairman of the Board of Directors	100,000
Members of the Board of Directors	50,000
Chairman of the Audit Committee	20,000
Members of the Audit Committee	10,000
Chairman of the Compensation Committee	15,000
Members of the Compensation Committee	7,500
Chairman of the Nomination Committee	10,000
Members of the Nomination Committee	5,000

Further, members of the board of directors may receive incentive-based remuneration under the Company's general guidelines for incentive pay to its members of the board of directors and executive management, ref. article 16 of the articles of association.

Finally, the board of directors proposed that each board member is granted warrants equal to the value of USD 150,000 calculated at the share price on the day of grant.

The proposal was adopted.

## **Re 7**

The board of directors proposed that the general meeting approved an authorization to the board of directors to issue warrants in accordance with the following provisions to be inserted in the Company's articles of association as article 5F:

*"Article 5F*

*The Board of Directors is until 03 April 2024 authorised, at one or more times, to issue up to 17,000,000 warrants, each conferring a right to subscribe for 1 share of nominal DKK 0.1 in the Company, and to implement the corresponding increase(s) of the share capital.*

*The warrants can be issued to employees, executive directors and board members in the Company and its subsidiaries without pre-emptive subscription rights for the Company's shareholders.*

*The exercise price for warrants, which are issued pursuant to the authorisation, shall at a minimum correspond to the market price of the Company's shares on the date of issuance of the warrants. The other terms for the warrants issued pursuant to this authorisation, including payment for the warrants, duration, exercise periods, vesting periods, adjustments as a result of corporate changes etc. shall be determined by the Board of Directors. The shares subscribed for on the basis of the issued warrants shall be negotiable shares issued to registered holders and shall be recorded in the Company's Register of Owners. The shares shall not have any restrictions as to their transferability and no shareholder shall be obliged to have their shares redeemed fully or partly.*

*The Board of Directors is entitled to make such amendments to the Articles of Association which are connected with the issuance of warrants comprised by this clause or the exercise thereof."*

The proposal was adopted.

## **Re 8**

The board of directors proposed that the general meeting approved an updated remuneration policy including general guidelines for incentive-based remuneration to members of the board of directors and executive management in accordance with the draft enclosed as exhibit 2 to the notice to convene the general meeting.

Compared to the remuneration policy that was approved in 2018 the only amendment was a limit increase of the board of directors' authorisation to offer the members of the executive management a one-time bonus from 3.0 to 3.45 percent in case of change of control.

The proposal was adopted.

As a consequence of the approval of the proposal, section 16 of the Company's articles of association was updated as follows:

*"On the general meeting held on 03 April 2019, the Company adopted general guidelines for incentive pay to the members of the board of directors and executive management."*

## **Re 9**

The board of directors proposed that the general meeting approved an authorisation to the board of directors to increase the Company's share capital at market price by cash payment with up to nominally DKK 17,181,953.50, corresponding to 10% of the Company's current nominal share capital, with or pre-emptive subscription rights for the shareholders

As a consequence of the proposed authorization the board of directors proposed that the following new provisions will be inserted in article 6 of the Company's articles of association:

### *"Article 6*

*The Board of Directors is until 03 April 2024 authorised, at one or more times, to increase the share capital by cash payment up to nominally DKK 17,181,953.50 at market price by issuing new shares, each with a nominal value of DKK 0.1, with pre-emptive subscription rights for the Company's shareholders.*

*The Board of Directors is until 03 April 2024 authorised, at one or more times, to increase the share capital by cash payment up to nominally DKK 17,181,953.50 at market price by issuing new shares, each with a nominal value of DKK 0.1, without pre-emptive subscription rights for the Company's shareholders.*

*The capital increases which the Board of Directors may decide pursuant to this authorisation cannot exceed a total aggregate nominal amount of DKK 17,181,953.50.*

*The new shares issued pursuant to this authorisation shall be negotiable shares issued to registered holders and shall be recorded in the Company's Register of Owners. The new shares shall not have any restrictions as to their transferability and no shareholder shall be obliged to have their shares redeemed fully or partly. The new shares shall carry the same rights as the Company's existing shares.*

*The Board of Directors shall decide on the further conditions for effecting the capital increases pursuant to the authorisation, including decision on when the rights attached to the new shares shall accrue. The Board of Directors is authorised to make the required amendments of the Articles of Association if the authorisation to increase the share capital is exercised."*

The proposal was adopted.

**Re 10**

The board of directors requested that the general meeting granted an authorisation until the next annual general meeting for the Company to acquire the Company's own shares for up to 10 per cent of the Company's share capital at any time, provided that the acquisition, in accordance with section 197 of the Danish Companies Act, can be financed by the funds that may be distributed as ordinary dividends. The payment may not deviate from the stock price at NASDAQ Copenhagen A/S with more than 10 per cent at the time of purchase.

The proposal was adopted.

**Re 11**

The board of directors proposed that the chairman of the annual general meeting, with the right of substitution, was authorized to file the resolutions passed by the general meeting for registration with the Danish Business Authority and to make such alterations or amendments as the Danish Business Authority may require for registration.

The proposal was adopted.

- 0 -

The chairman of the general meeting announced that all the items on the agenda had been discussed, thanked those present for an orderly general meeting and announced that the annual general meeting had come to an end.

The chairman of the board of directors thanked the shareholders for their attendance and good questions.

The general meeting adjourned.

- 0 -

Thus adopted at the annual general meeting on 3 April 2019.

As chairman of the meeting:



Thomas Holst Laursen